Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Buy
58
FMS Quote, Financials, Valuation and Earnings
Last price:
$23.06
Seasonality move
:
2.45%
Day range:
$22.96 - $23.28
52-week range:
$22.05 - $30.46
Dividend yield:
3.53%
P/E ratio:
16.73x
P/S ratio:
0.62x
P/B ratio:
0.89x
Volume:
363K
Avg. volume:
428.6K
1-year change:
2.95%
Market cap:
$13.5B
Revenue:
$20.9B
EPS (TTM):
$1.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
$5.8B | $0.57 | 2.77% | 407.8% | $28.51 |
|
BNTX
BioNTech SE
|
$255M | -$2.55 | -23.93% | -40.26% | $139.33 |
|
CVAC
CureVac NV
|
$15.4M | -$0.11 | 0.04% | -32.36% | $5.31 |
|
EVO
Evotec SE
|
$233M | -$0.01 | 17.8% | -75.1% | $5.4436 |
|
IFRX
InflaRx NV
|
$8.2K | -$0.19 | -74.55% | -37.98% | $10.34 |
|
IMTX
Immatics NV
|
$14.2M | -$0.45 | -81.87% | -704.25% | $19.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
$23.06 | $28.51 | $13.5B | 16.73x | $0.81 | 3.53% | 0.62x |
|
BNTX
BioNTech SE
|
$99.85 | $139.33 | $25.1B | 191.55x | $0.00 | 0% | 6.79x |
|
CVAC
CureVac NV
|
$4.66 | $5.31 | $1B | 6.52x | $0.00 | 0% | 12.94x |
|
EVO
Evotec SE
|
$3.6600 | $5.4436 | $1.3B | -- | $0.00 | 0% | 1.56x |
|
IFRX
InflaRx NV
|
$1.04 | $10.34 | $70.5M | -- | $0.00 | 0% | 321.34x |
|
IMTX
Immatics NV
|
$9.17 | $19.13 | $1.1B | 42.21x | $0.00 | 0% | 12.25x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
44.71% | 0.760 | 74.22% | 0.78x |
|
BNTX
BioNTech SE
|
1.31% | 1.387 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 2.758 | 3.39% | 1.84x |
|
EVO
Evotec SE
|
37.72% | 1.418 | 44.12% | 1.05x |
|
IFRX
InflaRx NV
|
2.1% | -0.265 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 1.667 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FMS
Fresenius Medical Care AG
|
$1.5B | $582M | 3.54% | 6.14% | 10.2% | $661M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
EVO
Evotec SE
|
-$72.4K | -$59.7M | -11.62% | -17.7% | -31.17% | -$101.3M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Fresenius Medical Care AG vs. Competitors
-
Which has Higher Returns FMS or BNTX?
BioNTech SE has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -1.89%. Fresenius Medical Care AG's return on equity of 6.14% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About FMS or BNTX?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 24.47%. On the other hand BioNTech SE has an analysts' consensus of $139.33 which suggests that it could grow by 39.54%. Given that BioNTech SE has higher upside potential than Fresenius Medical Care AG, analysts believe BioNTech SE is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 BNTXBioNTech SE13 5 0 -
Is FMS or BNTX More Risky?
Fresenius Medical Care AG has a beta of 0.907, which suggesting that the stock is 9.271% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.393, suggesting its more volatile than the S&P 500 by 39.311%.
-
Which is a Better Dividend Stock FMS or BNTX?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.53%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or BNTX?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than BioNTech SE quarterly revenues of $1.8B. Fresenius Medical Care AG's net income of $382.5M is higher than BioNTech SE's net income of -$33.5M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 16.73x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.62x versus 6.79x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.62x 16.73x $5.7B $382.5M BNTXBioNTech SE6.79x 191.55x $1.8B -$33.5M
-
Which has Higher Returns FMS or CVAC?
CureVac NV has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -5832.47%. Fresenius Medical Care AG's return on equity of 6.14% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About FMS or CVAC?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 24.47%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 14.28%. Given that Fresenius Medical Care AG has higher upside potential than CureVac NV, analysts believe Fresenius Medical Care AG is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 CVACCureVac NV1 3 0 -
Is FMS or CVAC More Risky?
Fresenius Medical Care AG has a beta of 0.907, which suggesting that the stock is 9.271% less volatile than S&P 500. In comparison CureVac NV has a beta of 1.842, suggesting its more volatile than the S&P 500 by 84.205%.
-
Which is a Better Dividend Stock FMS or CVAC?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.53%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or CVAC?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than CureVac NV quarterly revenues of $63.3M. Fresenius Medical Care AG's net income of $382.5M is higher than CureVac NV's net income of $319.3M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 16.73x while CureVac NV's PE ratio is 6.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.62x versus 12.94x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.62x 16.73x $5.7B $382.5M CVACCureVac NV12.94x 6.52x $63.3M $319.3M
-
Which has Higher Returns FMS or EVO?
Evotec SE has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -26.29%. Fresenius Medical Care AG's return on equity of 6.14% beat Evotec SE's return on equity of -17.7%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B EVOEvotec SE-0.04% -$0.14 $1.5B -
What do Analysts Say About FMS or EVO?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 24.47%. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 49.3%. Given that Evotec SE has higher upside potential than Fresenius Medical Care AG, analysts believe Evotec SE is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 EVOEvotec SE1 0 0 -
Is FMS or EVO More Risky?
Fresenius Medical Care AG has a beta of 0.907, which suggesting that the stock is 9.271% less volatile than S&P 500. In comparison Evotec SE has a beta of 1.785, suggesting its more volatile than the S&P 500 by 78.468%.
-
Which is a Better Dividend Stock FMS or EVO?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.53%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or EVO?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than Evotec SE quarterly revenues of $191.5M. Fresenius Medical Care AG's net income of $382.5M is higher than Evotec SE's net income of -$50.3M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 16.73x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.62x versus 1.56x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.62x 16.73x $5.7B $382.5M EVOEvotec SE1.56x -- $191.5M -$50.3M
-
Which has Higher Returns FMS or IFRX?
InflaRx NV has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -51538.49%. Fresenius Medical Care AG's return on equity of 6.14% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About FMS or IFRX?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 24.47%. On the other hand InflaRx NV has an analysts' consensus of $10.34 which suggests that it could grow by 894.59%. Given that InflaRx NV has higher upside potential than Fresenius Medical Care AG, analysts believe InflaRx NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 IFRXInflaRx NV5 2 0 -
Is FMS or IFRX More Risky?
Fresenius Medical Care AG has a beta of 0.907, which suggesting that the stock is 9.271% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.443, suggesting its more volatile than the S&P 500 by 44.312%.
-
Which is a Better Dividend Stock FMS or IFRX?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.53%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or IFRX?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than InflaRx NV quarterly revenues of $27.8K. Fresenius Medical Care AG's net income of $382.5M is higher than InflaRx NV's net income of -$14.3M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 16.73x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.62x versus 321.34x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.62x 16.73x $5.7B $382.5M IFRXInflaRx NV321.34x -- $27.8K -$14.3M
-
Which has Higher Returns FMS or IMTX?
Immatics NV has a net margin of 6.7% compared to Fresenius Medical Care AG's net margin of -974.45%. Fresenius Medical Care AG's return on equity of 6.14% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital FMSFresenius Medical Care AG25.43% $0.55 $28.6B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About FMS or IMTX?
Fresenius Medical Care AG has a consensus price target of $28.51, signalling upside risk potential of 24.47%. On the other hand Immatics NV has an analysts' consensus of $19.13 which suggests that it could grow by 108.56%. Given that Immatics NV has higher upside potential than Fresenius Medical Care AG, analysts believe Immatics NV is more attractive than Fresenius Medical Care AG.
Company Buy Ratings Hold Ratings Sell Ratings FMSFresenius Medical Care AG1 3 1 IMTXImmatics NV9 0 0 -
Is FMS or IMTX More Risky?
Fresenius Medical Care AG has a beta of 0.907, which suggesting that the stock is 9.271% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.360, suggesting its more volatile than the S&P 500 by 35.986%.
-
Which is a Better Dividend Stock FMS or IMTX?
Fresenius Medical Care AG has a quarterly dividend of $0.81 per share corresponding to a yield of 3.53%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fresenius Medical Care AG pays 57.49% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Fresenius Medical Care AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios FMS or IMTX?
Fresenius Medical Care AG quarterly revenues are $5.7B, which are larger than Immatics NV quarterly revenues of $6.1M. Fresenius Medical Care AG's net income of $382.5M is higher than Immatics NV's net income of -$59.1M. Notably, Fresenius Medical Care AG's price-to-earnings ratio is 16.73x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fresenius Medical Care AG is 0.62x versus 12.25x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FMSFresenius Medical Care AG0.62x 16.73x $5.7B $382.5M IMTXImmatics NV12.25x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
